Clinical data | |
---|---|
Trade names | Mycobutin[1] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a693009 |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 85% |
Protein binding | 85% |
Metabolism | Liver |
Elimination half-life | 28 to 62 hours (mean) |
Excretion | Kidney and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.133.627 |
Chemical and physical data | |
Formula | C46H62N4O11 |
Molar mass | 847.019 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Rifabutin (Rfb) is an antibiotic used to treat tuberculosis and prevent and treat Mycobacterium avium complex.[1] It is typically only used in those who cannot tolerate rifampin such as people with HIV/AIDS on antiretrovirals.[1] For active tuberculosis it is used with other antimycobacterial medications.[1] For latent tuberculosis it may be used by itself when the exposure was with drug-resistant TB.[1]
Rifabutin was approved for medical use in the United States in 1992.[1] It is on the World Health Organization's List of Essential Medicines.[3]